FDA Approves SPEVIGO for Generalized Pustular Psoriasis Flares

TUESDAY, Sept. 6, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
SPEVIGO is a novel, selective antibody infusion that blocks the activation of the interleukin-36 receptor, which is part of an immune system signaling pathway thought to be involved in the cause of GPP. The approval was based on a 12-week trial in which 53 patients with a GPP flare were treated with SPEVIGO or placebo. After one week, more patients treated with SPEVIGO showed no visible pustules than those treated with placebo (54 versus 6 percent).
The most common adverse reactions (≥5 percent) reported in patients taking SPEVIGO were asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection.
“GPP flares can greatly impact a patient’s life and lead to serious, life-threatening complications,” Mark Lebwohl, M.D., lead investigator for the trial, said in a statement. “The approval of SPEVIGO is a turning point for dermatologists and clinicians.”
Approval of SPEVIGO was granted to Boehringer Ingelheim.
Was this page helpful?
Related Posts
Rare, Deadly Bacterial Illness Now in United States, CDC Warns
THURSDAY, July 28, 2022 (HealthDay News) -- A bacteria that causes a rare but...
New Omicron Subvariant Causing COVID-19 Spike in South Africa
FRIDAY, April 29, 2022 (HealthDay News) -- A new omicron subvariant called BA.4...
La grasa en la cintura en la mediana edad podría significar fragilidad en la vejez
MARTES, 24 de enero de 2023 (HealthDay News) -- Cualquier aumento de exceso de...
Estudios en escuelas de Reino Unido no encuentran que el mindfulness beneficie a la salud mental de los niños
MIÉRCOLES, 13 de julio de 2022 (HealthDay News) -- Mientras las tasas de...